Comparing doxycycline and TMP-SMX for treating skin infections
Short and long term outcomes of doxycycline versus TMP-SMX for SSTI treatment
This study is looking at how well doxycycline works compared to another antibiotic, trimethoprim-sulfamethoxazole, for treating skin infections that are common in the community, so doctors can choose the best treatment for you.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center NIH-funded |
| Lab location | 1 site (Torrance, United States) |
| Project ID | NIH-10457315 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of doxycycline compared to trimethoprim-sulfamethoxazole (TMP-SMX) in treating community-associated skin and soft tissue infections (SSTIs). The study aims to gather high-quality clinical trial data to guide physicians in prescribing the most effective antibiotic treatment for these infections, which have seen a significant rise in incidence. Patients will be monitored for both short and long-term outcomes, including rates of recurrence and resistance to antibiotics. The research focuses on understanding how these treatments perform in real-world settings, particularly in light of increasing antibiotic resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research include adults and children aged 0-21 who are experiencing community-associated skin and soft tissue infections.
Not a fit: Patients with SSTIs caused by antibiotic-resistant bacteria that are not addressed by doxycycline or TMP-SMX may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients suffering from skin infections, potentially reducing recurrence rates and improving overall health outcomes.
How similar studies have performed: Previous studies have shown promising results with similar antibiotic comparisons, indicating that this research builds on established findings in the field.
Where this research is happening
Torrance, United States
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center — Torrance, United States (Active)
Researchers
- Principal investigator: Miller, Loren G. — Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Study coordinator: Miller, Loren G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.